WHO & WHY?

Suzanne Vernon: "Agency heads are scared to death...if XMRV works out"

Discussion in 'Action Alerts and Advocacy' started by CBS, Feb 23, 2011.

Page 1 of 4 1 2 3 4 Next >

"Agency heads are scared to death of how the patient population will react if XMRV works out." - Suzanne Vernon, September 11th, Lobby of the Salt Lake City Downtown Hilton – During a break at the 2010 OFFER Utah Patient Education Conference

September 11, 2010 ***November 2011***

Because in 1991 ONE million Americans were Infected with HIV in 2010 when studies showed between 10-25 million Americans were infected with XMRVs which likely got into humans via contaminated blood and vaccines

Vaccination is not Immunization, It's Extermination/Sterilization

HIV=FIRST GOF Injected in HBV vaccine & AZT In Asymptomatic Carriers

LAV Isolation in GRID-1982







AIDS. 2016 Sep 24;30(15):2289-98. doi: 10.1097/QAD.0000000000001201.

Standard vaccines increase HIV-1 transcription during antiretroviral therapy.

Yek C[1], Gianella S, Plana M, Castro P, Scheffler K, García F, Massanella M, Smith DM.

Author information

Abstract

OBJECTIVES: Curative strategies using agents to perturb the HIV reservoir have demonstrated only modest activity, whereas increases in viremia after standard vaccination have been described. We investigated whether vaccination against non-HIV pathogens can induce HIV transcription and thereby play a role in future eradication strategies.

HIV First Fauci GOF 1984
HIV/LAV EM Antibodies DIFFERENT

HIV DID NOT EXIST IN NATURE

November 7,1991 MAGIC TESTS POSITIVE FOR HIV ANTIBODIES
November 14, 1991 MIKOVITS THESIS: HIV Latency in Monocyte

HIV COULD NOT CAUSE AIDS IF INNATE IMMUNITY Healthy

If my people , who are called by my name, will humble themselves, pray & seek my face & turn from their wicked ways, then I hear from heaven, and I will forgive their Sin and will heal their land ***(2 Chronicles 7:14)***

AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 36, Number 7, 2020
Mary Ann Liebert, Inc.
DOI: 10.1089/aid.2020.0095

COMMENTARY

Fake Science: XMRV, COVID-19, and the Toxic Legacy of Dr. Judy Mikovits

Stuart J.D. Neil[1] and Edward M. Campbell[2]

Abstract

One cannot spend >5 min on social media at the moment without finding a link to some conspiracy theory or other regarding the origin of SARS-CoV2, the coronavirus responsible for the COVID-19 pandemic. From the virus being deliberately released as a bioweapon to pharmaceutical companies blocking the trials of natural remedies to boost their dangerous drugs and vaccines, the Internet is rife with far-fetched rumors. And predictably, now that the first immunization trials have started, the antivaccine lobby has latched on to most of them. In the last week, the trailer for a new "bombshell documentary" *Plandemic* has been doing the rounds, gaining notoriety for being repeatedly removed from YouTube and Facebook. We usually would not pay much heed to such things, but for retrovirologists like us, the name associated with these claims is unfortunately too familiar: Dr. Judy Mikovits.

THE RECOMBINANT ORIGIN OF SARS-COV2 October 2004



JOURNAL OF VIROLOGY, Oct. 2004, p. 10628–10635 Vol. 78, No.
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.19.10628–10635.2004

Retroviruses Pseudotyped with the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Efficiently Infect Cells Expressing Angiotensin-Converting Enzyme 2

Michael J. Moore,[1] Tatyana Dorfman,[1] Wenhui Li,[1] Swee Kee Wong,[1] Yanhan Li,[2] Jens H. Kuhn,[1,3] James Coderre,[4] Natalya Vasilieva,[5] Zhongchao Han,[2] Thomas C. Greenough,[4] Michael Farzan,[1]* and Hyeryun Choe[5]*

Partners AIDS Research Center, Brigham and Women's Hospital, and Department of Medicine (Microbiology and Molecular Genetics),[1] and Perlmutter Laboratory, Children's Hospital, and Department of Pediatrics,[5] Harvard Medical School, Boston, and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester,[4] Massachusetts; State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China[2]; and Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin, Berlin, Germany[3]

Received 3 February 2004/Accepted 28 May 2004

responses to potential vaccines. Here we show that simian immunodeficiency virus (SIV) pseudotyped with several codon-optimized S-protein variants could efficiently infect Vero E6 cells and HEK293T cells transiently or stably expressing ACE2. One such variant, truncated at its cytoplasmic tail and bearing instead a region of the tail of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (17), was especially efficient at mediating infection. Murine leukemia virus (MLV) pseudotyped with this S-protein variant also infected ACE2-expressing cells more efficiently than MLV pseudotyped with other S-protein variants. We used this sys-

JVI
Journals.ASM.org

Metagenomic Analysis of Viruses from Bat Fecal Samples Reveals Many Novel Viruses in Insectivorous Bats in China

Xingyi Ge,[a] Yan Li,[a] Xinglou Yang,[a] Huajun Zhang,[a] Peng Zhou,[a] Yunzhi Zhang,[b] and Zhengli Shi[a]

State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China,[a] and Yunnan Institute of Endemic Diseases Contro Prevention, Dali, China[b]

Received 31 October 2011 **Accepted** 31 January 2012

Published ahead of print 15 February 2012

Address correspondence to Zhengli Shi, zlshi@wh.iov.cn.

Supplemental material for this article may be found at http://jvi.asm.o

doi:10.1128/JVI.06671-11





Metagenomic Analysis of Viruses from the Bat Fecal Samples Reveals Many Novel Viruses in Insectivorous Bats in China

Xingyi Ge[1], Yan Li[1], Xinglou Yang[1], Huajun Zhang[1], Peng Zhou[1], Yunzhi Zhang[2], Zhengli Shi[1*]

Retro-transcribing viruses		
HERV-H/env60	1	*Retroviridae;* unclassified Retroviridae; *Human endogenous retrovirus*
Amphotropic murine leukemia virus	1	
Moloney murine sarcoma virus	1	*Retroviridae; Orthoretrovirinae; Gammaretrovirus*
Xenotropic MuLV-related virus VP62	1	
Moloney murine leukemia virus	5	
Friend murine leukemia virus	1	

NOTHING in CDC Schedule is a “VACCINE” ALL ARE Synthetic Viruses Bioweapons that activate your own cells to become pathogen





NEITHER Pararetrovirus SARS-COV2 Monkey Virus or synthetic Virus CALLED COVID VACCINE CAN CAUSE COVID if NOT Injected

Omnitüra Therapeutics

Combination therapy for prostate cancer using botanical compositions and bicalutamide

WO 2012061790 A1

ABSTRACT

Botanical compositions comprising non-alcoholic organic extracts of Ganoderma lucidum, Salvia miltiorrhiza, and Scutellaria barbata for use in conjunction with bicalutamide therapy fpr cancer therapy, are provided. Methods for treatment or therapy of prostate cancer in a human is provided, the method comprising: administering an effective amount of a botanical composition that is effective for reducing androgen receptor protein expression; and administering concurrently an effective amount of a compound having anti-androgen activity, wherein the concurrent administration of the compound and the botanical composition achieves a therapeutic effect that is more effective than either agent alone.

Publication number	WO2012061790 A1
Publication type	Application
Application number	PCT/US2011/059471
Publication date	May 10, 2012
Filing date	Nov 4, 2011
Priority date	Nov 4, 2010
Also published as	CA2816855A1, CN103327994A, 4 More »4 More »
Inventors	James Dao, Jeffrey Dao, 8 More »8 More »
Applicant	Genyous Biomed International
Export Citation	BiBTeX, EndNote, RefMan

Patent Citations (7), Non-Patent Citations (52), Referenced by (3), Classifications (10), Legal Events (4)

External Links: Patentscope, Espacenet

A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY HARNESSING THE POWER OF PLANTS.



HIV GP120 Spike : GPR15 is a G-Protein that acts as a Chemokine receptor for HIV "Lyme" disease=HIV Neuro AIDS also implicated in Various Lymphoma

- ANTIBODY Test identified XMRV ENV/Spike Syncytin pathology
  - Including infection of brain microglia
  - Infection and dysregulation of gut tight junctions
  - Vasculitis
  - Inflammatory dysfunction: cytokine/chemokine
  - autoimmunity

International Journal of *Molecular Sciences*

MDPI

Article

G Protein-Coupled Receptor 15 Expression Is Associated with Myocardial Infarction

brain sciences

MDPI

Review

Lyme Neuroborreliosis: Mechanisms of *B. burgdorferi* Infection of the Nervous System

Xenotropic Murine Leukemia Virus-Related Virus (XMRV)





Like mouse xenotropic MuLV, XMRV uses the Xpr-1 receptor to enter cells (Dong et al., PNAS, 2007)

An infectious clone was constructed and sequenced and found to be a novel gammaretrovirus (Dong et al., PNAS, 2007)

XMRV proviral integration occurs preferentially in CpG islands: gene promoters (Kim et al., JVirol, 2008)

and *GPR15* [129]. Of the genes identified, only *GPR15* is associated with an immune response [154]. GPR15 is a G-protein coupled receptor that acts as a chemokine receptor for human immunodeficiency virus (HIV) 1 and 2, and has been implicated in various lymphomas [154]. *CCDC163P* and *ZNF266* are involved in protein binding, with the latter



Residual DNA/RNA deriving from cultured cells - Total amount of DNA: 1.7-3.7 µg/dose, the 80% of which was human (Human fetal DNA / RNA from the MRC-5 cell line). Other amount of DNA: chicken

JVI
Journals.ASM.org

Generation of Multiple Replication-Competent Retroviruses through Recombination between PreXMRV-1 and PreXMRV-2

Krista Delviks-Frankenberry,[a] Tobias Paprotka,[a]* Oya Cingöz,[c]* Sheryl Wildt,[d] Wei-Shau Hu,[b] John M. Coffin,[c] Vinay K. Pathak[a]

Viral Mutation Section[a] and Viral Recombination Section,[b] HIV Drug Resistance Program, National Cancer Institute—Frederick, Frederick, Maryland, USA; Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, USA[c]; Harlan Laboratories, Indianapolis, Indiana, USA[d]

CHARACTERIZATION of gamma retrovirus isolated 15 years ago in ME/CFS

REPORT

Recombinant Origin of the Retrovirus XMRV

TOBIAS PAPROTKA, KRISTA A. DELVIKS-FRANKENBERRY, OYA CINGÖZ, ANTHONY MARTINEZ, HSING-JIEN KUNG, CLIFFORD G. TEPPER, WEI-SHAU HU, MATTHEW J. FIVASH. JR., JOHN M. COFFIN, AND VINAY K. PATHAK fewer Authors Info & Affiliations

SCIENCE • 31 May 2011 • Vol 333, Issue 6038 • pp. 97-101 • DOI: 10.1126/science.1205292

Abstract

The retrovirus XMRV (xenotropic murine leukemia virus–related virus) has been detected in human prostate tumors and in blood samples from patients with chronic fatigue syndrome, but these findings have not been replicated. We hypothesized that

Partial molecular cloning of the JHK retrovirus using gammaretrovirus consensus PCR primers

Brian D Halligan[1], Hai-Yuan Sun[2], Vladimir M Kushnaryov[2] & Sidney E Grossberg*[2]

[1]Biotechnology & Bioengineering Center, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA

[2]Department of Microbiology & Molecular Genetics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA

*Author for correspondence: Tel.: +1 414 276 8194 ▪ segrossb@gmail.com

The JHK virus (JHKV) was previously described as a type C retrovirus that has some distinctive ultrastructural features and replicates constitutively in a human B-lymphoblastoid cell line, JHK-3. In order to facilitate the cloning of sequences

Future Virology

Mikovits and Ruscetti file the patent for the PCR detection XMRV and Variants: SARSCOV2, XMRV2/Omicron April 6, 2010

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
61/321,147	04/06/2010		110	40000377-0001Var		

CONFIRMATION NO. 7100

FILING RECEIPT

26263
SONNENSCHEIN NATH & ROSENTHAL LLP
P.O. BOX 061080
WACKER DRIVE STATION, WILLIS TOWER
CHICAGO, IL 60606-1080

OC000000041244580

Date Mailed: 04/23/2010

Receipt is acknowledged of this provisional patent application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Applicant(s)

Judy A. Mikovits, Reno, NV;
Francis W. Ruscetti, New Market, MD;

Power of Attorney:
Saul Zackson--52391

TITLE OF THE INVENTION (500 characters max):
Diagnostic Identification of Variants of Xenotropic Murine Leukemia Virus-Related Virus



2017 Doctors who ROCK BADASS AWARD

frontiers in Public Health

PERSPECTIVE
published: 22 May 2017
doi: 10.3389/fpubh.2017.00108

Check for updates

XMRV and Public Health: The Retroviral Genome Is Not a Suitable Template for Diagnostic PCR, and Its Association with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Appears Unreliable

(i) specific, spurious annealing of the available primers in multiple homologous sites of the human genome;
(ii) strict homologies between whole XMRV genome and interspersed repetitive elements widespread in mammalian genomes

In conclusion, the occurrence of highly conserved, repeated DNA sequences in the XMRV genome deeply undermines the reliability of diagnostic PCRs by leading to artifactual and spurious amplifications. Together with all the other evidences, this makes the association between the XMRV retrovirus and CFS totally unreliable.

Imbalanced type I IFN Response to RNA Viruses Drives Development of Autoimmune ,Auto-inflammatory Disease & Cancer



Graphical Abstract



Authors

Daniel Blanco-Melo, Benjamin E. Nilsson-Payant, Wen-Chun Liu, ..., Jean K. Lim, Randy A. Albrecht, Benjamin R. tenOever

Correspondence

res2025@med.cornell.edu (R.E.S.), jean.lim@mssm.edu (J.K.L.), randy.albrecht@mssm.edu (R.A.A.), benjamin.tenoever@mssm.edu (B.R.t.)

In Brief

In comparison to other respiratory viruses, SARS-CoV-2 infection drives a lower antiviral transcriptional response that is marked by low IFN-I and IFN-III levels and elevated chemokine expression, which could explain the pro-inflammatory disease state associated with COVID-19.

XMRV controversy prevented publication of key Immune data generated BEFORE initiation of Collaboration with SIlverman

In: Chronic Fatigue Syndrome
Editors: Connor Hudson

ISBN: 978-1-63321-961-8

Chapter VI

Innate I mmune Changes in the Peripheral Blood of Chronic Fatigue Syndrome Patients: Risk Factors for Disease Progression and Management

Deborah L. S. Goetz[1], Judy A. Mikovits[2], Jamie Deckoff-Jones[3] and Francis W. Ruscetti[2]

[1]LANDRES Management Consultant LLC
[2]MAR Consulting Inc.
[3]Private CFS Practice

INIP AWARDED 2007:
Identified Cytokine Signature of XMRV associated disease! COVID?

Ancient viral protein enrages astrocytes in multiple sclerosis

Mark P Mattson & Dennis D Taub 2004

Syncytin is a viral envelope protein encoded in the human genome. New work in this issue indicates that it is activated in multiple sclerosis astrocytes and microglia, contributing to the inflammation-induced myelin destruction that causes disease symptoms.



in vivo 25: 307-314 (2011)

Xenotropic Murine Leukemia Virus-related Virus-associated Chronic Fatigue Syndrome Reveals a Distinct Inflammatory Signature

VINCENT C. LOMBARDI[1], KATHRYN S. HAGEN[1], KENNETH W. HUNTER[4], JOHN W. DIAMOND[2†], JULIE SMITH-GAGEN[3], WEI YANG[3] and JUDY A. MIKOVITS[1]



Figure 2. *Random Forest prediction. Horizontal bars represent the relative importance that each cytokine or chemokine contributes to the predictive nature of the signature.*

“We also introduce chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)” Moreover, HERVs have also been associated with other diseases such as schizophrenia and bipolar disorder, type 1 diabetes



Chronic inflammatory demyelinating polyneuropathy (CIDP): a peripheral nervous system disease and the commonest chronic immune-mediated peripheral neuropathy that takes either a relapsing or progressive course. Clinically it manifests by the development of weakness and sensory disturbance that lead to marked disability. Multifocal inflammation and stripping of myelin sheaths by macrophages are thought to result from aberrant immune responses, mediated by T and/or B lymphocytes, against peripheral nerve antigens.

WAIT!! I Thought the XMRV Findings Had Been Discredited!

"Designed to Fail"

Lipkin Multi-Center Study (2012) – The Great Debunker!!!!

1. Medical or psychiatric condition that might be associated with fatigue
2. Abnormal serum characteristics
3. Abnormal thyroid functions
4. Lyme disease spirochete
5. Treponema pallidium (tapeworm)
6. Hepatitis B or C virus
7. HIV infection



"We found retroviruses in 85 percent of the sample pools. Again, it is very difficult to know whether this is clinically significant or not. And given the previous experience with retroviruses in chronic fatigue, I am going to be very clear in telling you, although I am reporting them in Professor Montoya's samples, neither he, nor we, have concluded there is a relationship to disease."

HOW MANY NEW VIRUSES HAVE WE CREATED CAUSING EXPLOSION CHRONIC DISEASE?

"*Science* Started this and *Science* is going to End This"

John Coffin to Frank Ruscetti, November 2010

Failure to Confirm XMRV/MLVs in the Blood of Patients with Chronic Fatigue Syndrome: A Multi-Laboratory Study

Graham Simmons,[1] Simone A. Glynn,[2] Anthony L. Komaroff,[3] Judy A. Mikovits,[4] Leslie H. Tobler,[1] John Hackett Jr.,[5] Ning Tang,[5] William M. Switzer,[6] Walid Heneine,[6] Indira K. Hewlett,[7] Jiangqin Zhao,[7] Shyh-Ching Lo,[8] Harvey J. Alter,[9] Jeffrey M. Linnen,[10] Kui Gao,[10] John M. Coffin,[11] Mary F. Kearney,[12] Francis W. Ruscetti,[12] Max A. Pfost,[4] James Bethel,[13] Steven Kleinman,[14] Jerry A. Holmberg,[15] Michael P. Busch,[1]* for the Blood XMRV Scientific Research Working Group (SRWG)†

12 September 2011; accepted 20 September 2011
Published online 22 September 2011;

Mikovits said she hopes to have full sequences of her new viruses "in a couple of weeks."

–JON COHEN

30 SEPTEMBER 2011 VOL 333 SCIENCE www.sciencemag.org

NEWS&ANALYSIS

VIROLOGY

The Waning Conflict Over XMRV And Chronic Fatigue Syndrome

OTTAWA, CANADA—Less than a day after a new study dealt what many consider a lethal blow to the controversial theory that a newly detected virus, XMRV, is linked to chronic fatigue syndrome (CFS), proponents and skeptics of the theory squared off in a meeting here.

In one corner was Judy Mikovits, research director at the Whittemore Peterson Institute for Neuro-Immune Disease (WPI) in Reno, Nevada, and the main champion of the idea that XMRV and its relatives play a role in CFS. Her opponent, an erstwhile supporter, was heavyweight retrovirologist John Coffin of the Tufts University Sackler School of Graduate Biomedical Sciences in Boston. When Mikovits and Coffin took the stage at the meeting, which was organized by IACFS/ME (an international association devoted to the disease) and attracted 460 researchers and patients, they sat on opposite sides of the lectern. During their introductions, Coffin clasped his hands in front of his mouth, looking like a man in

had asserted—explained the XMRV DNA it found in some patient samples.

In Ottawa, Mikovits came out swinging. But she didn't make the case for XMRV, which stands for xenotropic murine leukemia virus–related virus. Instead, she offered new evidence that people with CFS (known as myalgic encephalomyelitis in some countries) had a virus "highly related" to XMRV.

Unlike the original study that appeared in *Science* that showed entire sequences of XMRV and infection of fresh cells, Mikovits revealed only partial viral sequences that she

Pro and con. Judy Mikovits (*left*) argued for the link between human

SCIENCE • 23
Sep2011 • Vol 333, Issue 6050 • pp. 1694-1701 • DOI: 10.1126/science.333.6050.1694

False Positive

NEWS

False Positive

By Jon Cohen, et al. | Sep 21st, 2011

Virology False Positive Jon **Cohen**, Martin Enserink A report in Science 2 years ago that linked a mouse retrovirus, XMRV, to chronic fatigue syndrome astonished scientists and patients alike. ... **COHEN**/SCIENCE If this seems like wordsmithing and splitting hairs, welcome to the confusing, maddening world of XMRV. ... In scientific circles, **Mikovits** has developed a less flattering reputation.

DOI: 10.1126/science.333.6050.1694 Science Vol. 333, No. 6050

Pathways shared in Autoimmune and Neuroimmune Disease



source: A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome; Morris & Maes; Metab Brain Dis. 2012 Jun 21

12/01/20 • BIG PHARMA › VIEWS www.childenshealthdefense.org

Under Guise of 'Racial Justice,' Johns Hopkins Lays Out Plan to Vaccinate Ethnic Minorities and Mentally Challenged First

Claims made by Johns Hopkins Center for Health Security about its strategy for vaccinating ethnic minorities and the mentally challenged first, "as a matter of justice," suggest ulterior motives.

New Technologies Reveal the presence of Multiple Gamma retroviruses in a single Human Cell Line

JVI
Journals.ASM.org

Detection of Murine Leukemia Virus in the Epstein-Barr Virus-Positive Human B-Cell Line JY, Using a Computational RNA-Seq-Based Exogenous Agent Detection Pipeline, PARSES

Zhen Lin,[a] Adriane Puetter,[a] Joseph Coco,[b] Guorong Xu,[b] Michael J. Strong,[a] Xia Wang,[a] Claire Fewell,[a] Melody Baddoo,[a] Christopher Taylor,[b] and Erik K. Flemington[a]

Tulane University Health Sciences Center and Tulane Cancer Center, New Orleans, Louisiana, USA,[a] and University of New Orleans, New Orleans, Louisiana, USA[b]









The Name Game and the Immaculate Recombination

How many have we created, John? How many "novel" retroviruses

Judy Mikovits asking a question to Dr. John Coffin
at the Ottawa IACFS ME/CFS meeting 23 September 2011

***Plague* Chap 17 p 284**

RESEARCH PAPER

Cancer Biology & Therapy 12:7, 617-628; October 1, 2011; © 2011 Landes Bioscience

Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts

Yu-An Zhang,[1] Anirban Maitra,[2] Jer-Tsong Hsieh,[3] Charles M. Rudin,[4] Craig D. Peacock,[4] Collins Karikari,[2] Rolf A. Brekken,[1] Victor Stastny,[1] Boning Gao,[1] Luc Girard,[1] Ignacio Wistuba,[5] Eugene Frenkel,[6] John D. Minna[1] and Adi F. Gazdar[1,*]

Table 3. Frequent detection of murine leukemia virus (MLV) contamination of non-xenograft human cultures

Characterization of murine leukemia viruses (MLV) detected in human non-xenograft cultures in xenograft culture laboratories

Table 1. Identification of xenotropic murine leukemia viruses (XMLV) and MLV-related viruses in xenograft cell lines

HHS And DOJ Committing Federal Crimes Against Innocent Victims: Vaccines Are Presumed Innocent at all Costs

The True Costs Buried with The Victims Of Unsafe and Untested Vaccines

Journal of Autism and Developmental Disorders
https://doi.org/10.1007/s10803-021-05120-7

ORIGINAL PAPER

Autism Tsunami: the Impact of Rising Prevalence on the Societal Cost of Autism in the United States

Mark Blaxill[1] · Toby Rogers[2] · Cynthia Nevison[3]

Accepted: 29 May 2021

Abstract
The cost of ASD in the U.S. is estimated using a forecast model that for the first time accounts for the true historical increase in ASD. Model inputs include ASD prevalence, census population projections, six cost categories, ten age brackets, inflation projections, and three future prevalence scenarios. Future ASD costs increase dramatically: total base-case costs of $223 (175–271) billion/year are estimated in 2020; $589 billion/year in 2030, $1.36 trillion/year in 2040, and $5.54 (4.29–6.78) trillion/year by 2060, with substantial potential savings through ASD prevention. Rising prevalence, the shift from child to adult-dominated costs, the transfer of costs from parents onto government, and the soaring total costs raise pressing policy questions and demand an urgent focus on prevention strategies.

IN THE UNITED STATES COURT OF FEDERAL CLAIMS
OFFICE OF SPECIAL MASTERS

CATHERINE GERTRUDE McCABE,

Petitioner,

v.

SECRETARY OF HEALTH AND HUMAN SERVICES,

Respondent.

No. 13-570V
SPECIAL MASTER
CHRISTIAN J. MORAN

RESPONDENT'S OPPOSITION TO PETITIONER'S REQUEST FOR FEES AND COSTS

On December 5, 2018, petitioner filed an Application for Attorneys' Fees and Costs ("Application"). Petitioner requested $113,034.65 in attorneys' fees and $73,610.58 in costs, for a total of $186,645.23. Application at 1. As explained below, the Secretary of Health and Human Services ("respondent") maintains that petitioner lost reasonable basis for her claim after the filing of respondent's expert report from Dr. Thomas Leist. Therefore, petitioner is not entitled to receive a discretionary attorneys' fees and costs award beyond February 20, 2015.

JVI
Journals.ASM.org

Nov 2013

Generation of Multiple Replication-Competent Retroviruses through Recombination between PreXMRV-1 and PreXMRV-2

Krista Delviks-Frankenberry,[a] Tobias Paprotka,[a]* Oya Cingöz,[c]* Sheryl Wildt,[d] Wei-Shau Hu,[b] John M. Coffin,[c] Vinay K. Pathak[a]

Viral Mutation Section[a] and Viral Recombination Section,[b] HIV Drug Resistance Program, National Cancer Institute—Frederick, Frederick, Maryland, USA; Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, USA[c]; Harlan Laboratories, Indianapolis, Indiana, USA[d]

- Are two RCRs made by passing human prostate tissue through mouse; XMRV, BRV4 (second recombinant infectious virus occurring in human cells)
- Additional XMRV-like viruses may exist
- They do not have to be the exact sequence of XMRV (VP62)

Whether we fail to see the clever virus which does not kill its host, but has learned to live with it
When a disease takes so much from a patient but stops just short of death,
how does the medical community respond?
Will the scientific community have the courage to answer the question of whether these diseases
Might have been of their own creation" ????"

Oral Immunizations for HIV ! Oral Therapies for Vaccine AIDS



AMERICAN SOCIETY FOR MICROBIOLOGY | Antimicrobial Agents and Chemotherapy®

100 Years of Suramin

Natalie Wiedemar,[a,b] Dennis A. Hauser,[a,b] Pascal Mäser[a,b]

Citation Wiedemar N, Hauser DA, Mäser P. 2020. 100 years of suramin. Antimicrob Agents Chemother 64:e01168-19. https://doi.org/10.1128/AAC.01168-19.

Address correspondence to Pascal Mäser, pascal.maeser@unibas.ch.

Accepted manuscript posted online 16 December 2019
Published 21 February 2020

SURAMIN, THE FRUIT OF EARLY MEDICINAL CHEMISTRY

SURAMIN AS AN ANTIPARASITIC DRUG

SURAMIN AS AN ANTIVIRAL AGENT

SURAMIN AGAINST CANCER

SURAMIN AS AN ANTIDOTE

Three of the many biological activities of suramin support its potential use as a protective agent: the inhibition of thrombin, the inhibition of phospholipase A2, and the inhibition of purinergic signaling.

FURTHER POTENTIAL USES OF SURAMIN

PNAS

An endogenous retroviral envelope syncytin and its cognate receptor identified in the viviparous placental *Mabuya* lizard

Guillaume Cornelis[a,b,1,2], Mathis Funk[a,b,1], Cécile Vernochet[a,b], Francisca Leal[c,3], Oscar Alejandro Tarazona[c,4], Guillaume Meurice[d], Odile Heidmann[a,b], Anne Dupressoir[a,b], Aurélien Miralles[e], Martha Patricia Ramirez-Pinilla[c], and Thierry Heidmann[a,b,5]

[a]Unité Physiologie et Pathologie Moléculaires des Rétrovirus Endogènes et Infectieux, CNRS UMR 9196, Gustave Roussy, Villejuif, F-94805, France; [b]UMR 9196, Université Paris-Sud, Orsay, F-91405, France; [c]Laboratorio de Biología Reproductiva de Vertebrados, Escuela de Biología, Universidad Industrial de Santander, 680002 Bucaramanga, Colombia; [d]Plateforme de Bioinformatique, INSERM U529/CNRS UMS3655, Gustave Roussy, Villejuif, F-94805, France; and [e]Institut de Systématique, Evolution, Biodiversité, Muséum National d'Histoire Naturelle, CNRS UPMC EPHE, Sorbonne Universités, Paris, F-75005, France

Edited by R. Michael Roberts, University of Missouri-Columbia, Columbia, MO, and approved October 26, 2017 (received for review August 28, 2017)

Significance

Retroviral envelope gene capture and exaptation for a placental function has been demonstrated in mammals. Remarkably, placental structures have also emerged on rare occasions in nonmammalian vertebrates, resulting in related modes of reproduction. The *Mabuya* lizard, which emerged 25 Mya, possesses a placenta closely related to that of mammals. Here, we identified a specific retroviral envelope gene capture that shows all the characteristic features of a bona fide mammalian syncytin, being conserved in *Mabuya* evolution, expressed in the placenta, and fusogenic. Together with the present identification of its cognate receptor, these results show that syncytin capture is not restricted to mammals and is likely to be a major driving force for placenta emergence.

TABLE 1 Diseases and pathogens susce

Disease and/or pathogen	Cell culture	Animal model	Patient
Parasitic infections			
T. b. rhodesiense HAT	X	X	X
T. brucei gambiense HAT	X	X	X
Surra, *T. evansi*	X	X	NA
River blindness, *O. volvulus*	X	X	X
T. cruzi	X		
Leishmania spp.	X		
P. falciparum	X		
Viral infections			
Hepatitis virus	X	X	X
AIDS, HIV	X		X
Herpes simplex virus	X	X	
Chikungunya virus	X	X	
Enterovirus 71	X	X	
Dengue virus	X		
Zika virus	X		
Ebola virus	X		
Neoplastic diseases			
Non-small cell lung cancer	X	X	
Breast cancer	X	X	
Bladder cancer	X	X	
Brain tumors	X	X	
Prostate cancer	X	X	X
Other			
Snakebite	X	X	
Arthritis	X	X	
Autism	NA	X	X

Suramin & Ivermectin: Purinergic Modulators important for restoring balance of Innate and adaptive Immunity





Annual Review of Immunology

Purine Release, Metabolism, and Signaling in the Inflammatory Response

Joel Linden,[1,2] Friedrich Koch-Nolte,[3] and Gerhard Dahl[4]

Annu. Rev. Immunol. 2019. 37:325–47

The *Annual Review of Immunology* is online at immunol.annualreviews.org



- modulator of the ATP/P2X4/P2X7 axis
- selectively targets immunosuppressive myeloid cells and Tregs
- functions as an RNA helicase
- an activator of chloride channel receptors
- inducer of mitochondrial dysfunction and oxidative stress

Both Inhibit Plasmodium parasite of the blood plasma that affects the oxygen carrying capacity of the red blood cells

EXPRESSION OF Synthetic model SYNCITIN IN COVID vaccines expected to result in female infertility and the Development of CANCER

Head of Pfizer Research: Covid Vaccine is Female Sterilization

Health & Money News / December 2, 2020 / News

The vaccine contains a **spike protein (see image) called syncytin-1**, vital for the formation of human placenta in women. If the vaccine works so that we form an immune response AGAINST the spike protein, we are also **training the female body to attack syncytin-1,** which could lead to infertility in women of an unspecified duration.

- The vaccinations are expected to produce antibodies against spike proteins of SARS-CoV-2. However, spike proteins also contain **syncytin-homologous proteins**, which are essential for the formation of the placenta in mammals such as humans. It must be absolutely ruled out that a vaccine against SARS-CoV-2 could trigger an immune reaction against syncytin-1, as otherwise **infertility of indefinite duration could result in vaccinated women**.
- The mRNA vaccines from BioNTech/Pfizer contain **polyethylene glycol (PEG)**. 70% of people develop antibodies against this substance – this means that many people can develop allergic, potentially fatal reactions to the vaccination.
- The much too short duration of the study does **not allow a realistic estimation of the late effects**.

Nevertheless, BioNTech/Pfizer apparently submitted an application for emergency approval on December 1, 2020.

Syncytin expressed from HERV required for **placenta** formation in mammals

part of the Spike Protein expected to make Antibodies

Pfizer filed for Emergency Approval, December 2020

An endogenous retroviral envelope syncytin and its cognate receptor identified in the viviparous placental *Mabuya* lizard

Guillaume Cornelis[a,b,1,2], Mathis Funk[a,b,1], Cécile Vernochet[a,b], Francisca Leal[c,3], Oscar Alejandro Tarazona[c,4], Guillaume Meurice[d], Odile Heidmann[a,b], Anne Dupressoir[a,b], Aurélien Miralles[e], Martha Patricia Ramirez-Pinilla[c], and Thierry Heidmann[a,b,5]

[a]Unite Physiologie et Pathologie Moléculaires des Rétrovirus Endogènes et Infectieux, CNRS UMR 9196, Gustave Roussy, Villejuif, F-94805, France; [b]UMR 9196, Université Paris-Sud, Orsay, F-91405, France; [c]Laboratorio de Biología Reproductiva de Vertebrados, Escuela de Biología, Universidad Industrial de Santander, 680002 Bucaramanga, Colombia; [d]Plateforme de Bioinformatique, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, F-94805, France; and [e]Institut de Systématique, Evolution, Biodiversité, Muséum National d'Histoire Naturelle, CNRS UPMC EPHE, Sorbonne Universités, Paris, F-75005, France

Edited by R. Michael Roberts, University of Missouri-Columbia, Columbia, MO, and approved October 26, 2017 (received for review August 23, 2017)

Significance

Retroviral envelope gene capture and exaptation for a placental function has been demonstrated in mammals. Remarkably, placental structures have also emerged on rare occasions in nonmammalian vertebrates, resulting in related modes of reproduction. The *Mabuya* lizard, which emerged 25 Mya, possesses a placenta closely related to that of mammals. Here, we identified a specific retroviral envelope gene capture that shows all the characteristic features of a bona fide mammalian syncytin, being conserved in *Mabuya* evolution, expressed in the placenta, and fusogenic. Together with the present identification of its cognate receptor, these results show that syncytin capture is not restricted to mammals and is likely to be a major driving force for placenta emergence.



PRO CHOICE IS PROLIFE

California Department of PublicHealth

https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA_adap_eligibility.aspx

THANKS TO HIV/AIDS ADVOCATES (ACT-UP) KAISER AND GOVT PAY FOR HIV TEST AND MEDICATIONS

AIDS Drug Assistance Program (ADAP) Eligibility

The AIDS Drug Assistance Program (ADAP) is for people diagnosed with HIV or AIDS. The program provides eligible California residents with:

- Free FDA-approved medications used in the treatment and suppression of HIV/AIDS and HIV/AIDS-related opportunistic infections (for a list of covered medications, please refer to the ADAP Formulary (PDF)
- Premium payment assistance for individuals enrolled in a private health insurance plan (for more information, visit the Health Insurance Premium Payment Assistance page)
- Premium payment assistance for individuals enrolled in a Medicare Part D prescription plan (for more information, visit Medicare Part D Premium Payment Assistance page)

Free FDA-approved HIV/AIDS medications (= $3400/month)

Insurance Premium Plus Tax Credit = up to 100% paid with NO copay

Eligibility Criteria

To be eligible for the ADAP program, a client must:

- Be a resident of California;
- Have a positive HIV/AIDS diagnosis;
- Be at least 18 years old;
- Have an annual Modified Adjusted Gross Income (MAGI) that does not exceed 500% Federal Poverty Level based on household size and income;
- Not be fully covered by Medi-Cal or any other third party payers.

Have a positive HIV/AIDS diagnosis

Earn less than $72,900/year

Flying Syringes “FILE UNDER UNWORKABLE BUT VERY COOL”

Ladner et al., 2016, Cell Host & Microbe *20*, 357–367
September 14, 2016 © 2016 Elsevier Inc.
http://dx.doi.org/10.1016/j.chom.2016.07.011

Graphical Abstract



Authors

Jason T. Ladner, Michael R. Wiley, Brett Beitzel, ..., Laura D. Kramer, Robert B. Tesh, Gustavo Palacios

Correspondence

jason.t.ladner.ctr@mail.mil (J.T.L.), gustavo.f.palacios.ctr@mail.mil (G.P

In Brief

Multicomponent viruses, which separately package different genome segments, were thought to be restricted to plant and fungal hosts. Ladner et al. characterize a multicomponent mosquito virus and describe an evolutionarily related, segmented virus in a nonhuman primate. These findings provide evidence for multicomponent animal viruses and suggest relevance to animal health.

NEWS CAREERS COMMENTARY JOURNALS Science LOG IN BECOME A MEMBER

News Home All News ScienceInsider News Features

HOME > NEWS > ALL NEWS > RESEARCHERS TURN MOSQUITOES INTO FLYING VACCINATORS

NEWS | ASIA

Researchers Turn Mosquitoes Into Flying Vaccinators

Insects could theoretically protect against various diseases, but concept is unlikely to take off

18 MAR 2010 • BY MARTIN ENSERINK

SHARE:

Here's a study to file under "unworkable but very cool." A group of Japanese researchers has developed a mosquito that spreads vaccine instead of disease. Even the researchers admit, however, that regulatory and ethical problems will prevent the critters from ever taking wing—at least for the delivery of human vaccines.

THEHIGHWIRE.COM

GOD's People are destroyed from lack of Knowledge (Hosea 4:6)

TheRealDrJudy.com
DrJudy@TheRealDrJudy.com
Plaguethebook.com
Shop.therealdrjudy.com

Dr. Judy & friends' highly censored books that document the real science, healing solutions and show how we end this plague of corruption!















Plandemic and Beyond:COVID19

A Scholar's Obligation in an Age of Corruption

2024 GOD WINS

we are the medicine
our love is our power



- Obligation to Educate
- Opportunity to learn
  - Recognize how the criminal forces of Media FDA,CDC, NIH lawyers conspire to perpetrate fraud

OPPORTUNITY TO FORM ALLIANCES!
Together we can END FOREVER the Centur
PLAGUE of CORRUPTION



Dr. Judy A. Mikovits
PhD Biochemistry Molecular Biol
www.plaguethebook.com
805-797-6967